Article
Bimekizumab effective across the axSpA spectrum - Nature Reviews Rheumatology
Rating:
0.0
Views:
32
Likes:
1
Library:
1
The IL-17A–IL-17F inhibitor bimekizumab is safe and effective for the treatment of both radiographic and non-radiographic axial spondyloarthritis, according to the results of two parallel phase III trials.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value